LATEST NEWS

IBM UK executive Dr Dave Watson appointed Commander of the Order of the British Empire (CBE) in the New Year 2017 Honours List

Her Majesty Queen Elizabeth II has appointed IBM (NYSE: IBM) executive Dr Dave Watson to be Commander of the Order of the British Empire (CBE) in the New Year 2017 Honours list.

Dr Watson’s citation notes his services to Science and Engineering Research.

As a Director of IBM Research, Dr Watson leads a team helping UK industry capitalise on emerging cognitive and high performance computing technologies. Application areas include high accuracy formulation in consumer goods, manufacturing challenges and life sciences projects such as precision agriculture, anti-microbial surfaces and genomics. He is based at IBM Hursley near Winchester.

Dr Watson also has a long history of involvement with the Engineering and Physical Sciences Research Council (EPSRC), the body that funds around £1B of research a year in UK universities. EPSRC supports subjects as diverse as Chemistry, IT, Materials, Mathematics, Physics, Engineering, and Electronics. His work with the council started in 2004 when he joined the Industrial Advisory Panel of EPSRC.

In 2007 he became Chair of the Research Councils UK Digital Economy Advisory Board and was appointed to Council, the governing body, of EPSRC in 2009. His term on Council was extended for a further four years in 2013. At that time, he joined the Audit and Risk Assurance Committee, a group he has chaired since 2014.

Commenting on the appointment, Arvind Krishna, senior vice president and director of IBM Research said “Dr Watson’s appointment is a well deserved accolade that exemplifies his contribution to help Britain research and be prepared for future technology evolutions. Over many years, he has dedicated his skills and expertise to help set research and also training in engineering and the physical sciences in the right direction to ensure that the world’s biggest problems and boundaries of knowledge continue to advance.”

David Stokes, Chief Executive IBM UK & Ireland said, “On behalf of all UK IBMers I want to congratulate Dave on this tremendous recognition. IBM has been a long serving member of the business community in this country and many IBMers over the years have contributed to important technology, business and social issues during this time. I am very proud of Dave’s contributions and pleased to see this long history continue.”

Dr Watson said, “I am immensely proud to have been given this honour. My work over the past 12 years with EPSRC has been very enriching and enjoyable in both a personal and business capacity. It is very interesting to be involved in how the UK handles the next generation of technological change. It is a privilege to work with the EPSRC Executive in Swindon and also to have spent time on Council with some of the UK’s most eminent scientists and engineers.”

Liat

Recent Posts

Tower Semiconductor Secures $1.3 Billion Silicon Photonics Agreements and Reports Strong Q1 2026 Growth

Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…

13 hours ago

14 Israeli Cybersecurity Companies Named to the Rising in Cyber 2026 List of the World’s Most Promising Cyber Startups

The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…

14 hours ago

Sequent Selected by 15 Canadian Municipalities to Deliver Verifiable, Trust-Based Digital Voting for Elections

More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…

14 hours ago

Sheba and Ichilov Medical Centers Join AccuLine’s International Clinical Trial for AI-Driven Early Heart Attack Risk Assessment

The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…

14 hours ago

Molex Completes Acquisition of Teramount Ltd.

Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…

4 days ago

Immunai Expands Oncology Collaboration, Extending AI-Driven Biomarker and Clinical Insights Through 2027

This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…

4 days ago